Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus Rituximab vs Lenalidomide plus Rituximab in R/R MZL
NCT06082102Phase 3Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Dec 2023
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by InnoCare Pharma. Started Dec 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06082102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082102.